دورية أكاديمية
أعرض في EDS

A comprehensive review of therapeutic approaches available for the treatment of cholera.

التفاصيل البيبلوغرافية
العنوان: A comprehensive review of therapeutic approaches available for the treatment of cholera.
المؤلفون: Sousa FBM; Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Post-graduation Program in Biotechnology, Federal University of Parnaíba Delta, Parnaíba, Brazil.; Northeast Biotechnology Network (RENORBIO), Federal University of Piauí, Teresina, Brazil., Nolêto IRSG; Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Post-graduation Program in Biotechnology, Federal University of Parnaíba Delta, Parnaíba, Brazil.; Northeast Biotechnology Network (RENORBIO), Federal University of Piauí, Teresina, Brazil., Chaves LS; Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Post-graduation Program in Biotechnology, Federal University of Parnaíba Delta, Parnaíba, Brazil.; Post-graduation Program in Biomedical Sciences, Federal University of Piauí, Parnaíba, Brazil., Pacheco G; Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Post-graduation Program in Biotechnology, Federal University of Parnaíba Delta, Parnaíba, Brazil., Oliveira AP; Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Post-graduation Program in Biotechnology, Federal University of Parnaíba Delta, Parnaíba, Brazil.; Northeast Biotechnology Network (RENORBIO), Federal University of Piauí, Teresina, Brazil., Fonseca MMV; Institute of Higher Education of Vale do Parnaíba (IESVAP), Parnaíba, Brazil., Medeiros JVR; Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (Lafidg), Post-graduation Program in Biotechnology, Federal University of Parnaíba Delta, Parnaíba, Brazil.; Northeast Biotechnology Network (RENORBIO), Federal University of Piauí, Teresina, Brazil.
المصدر: The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 2020 Dec; Vol. 72 (12), pp. 1715-1731. Date of Electronic Publication: 2020 Jul 31.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 0376363 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-7158 (Electronic) Linking ISSN: 00223573 NLM ISO Abbreviation: J Pharm Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2021- : [Oxford] : Oxford University Press
Original Publication: London : Pharmaceutical Society of Great Britain
مواضيع طبية MeSH: Anti-Bacterial Agents/*therapeutic use , Cholera/*drug therapy , Vibrio cholerae/*drug effects, Animals ; Anti-Bacterial Agents/adverse effects ; Cholera/diagnosis ; Cholera/microbiology ; Cholera Toxin/metabolism ; Combined Modality Therapy ; Fluid Therapy ; Host-Pathogen Interactions ; Humans ; Molecular Targeted Therapy ; Rehydration Solutions/therapeutic use ; Treatment Outcome ; Vibrio cholerae/metabolism ; Vibrio cholerae/pathogenicity ; Virulence Factors/metabolism
مستخلص: Objectives: The oral rehydration solution is the most efficient method to treat cholera; however, it does not interfere in the action mechanism of the main virulence factor produced by Vibrio cholerae, the cholera toxin (CT), and this disease still stands out as a problem for human health worldwide. This review aimed to describe therapeutic alternatives available in the literature, especially those related to the search for molecules acting upon the physiopathology of cholera.
Key Findings: New molecules have offered a protection effect against diarrhoea induced by CT or even by infection from V. cholerae. The receptor regulator cystic fibrosis channel transmembrane (CFTR), monosialoganglioside (GM1), enkephalinase, AMP-activated protein kinase (AMPK), inhibitors of expression of virulence factors and activators of ADP-ribosylarginine hydrolase are the main therapeutic targets studied. Many of these molecules or extracts still present unclear action mechanisms.
Conclusions: Knowing therapeutic alternatives and their molecular mechanisms for the treatment of cholera could guide us to develop a new drug that could be used in combination with the rehydration solution.
(© 2020 Royal Pharmaceutical Society.)
References: Harris JB et al. Cholera. Lancet 2012; 379: 2466-2476.
Davies HG et al. Cholera - management and prevention. J Infect 2017; 74: S66-S73.
Jutla A et al. Natural disasters and cholera outbreaks: current understanding and future outlook. Curr Environ Health Rep 2017; 4: 99-107.
Lippi D et al. Cholera. Microbiol Spectr 2016; 4: 1-6.
CDC (Centers for Disease Control and Prevention). Cholera-Vibrio cholerae Infection. 2018. https://www.cdc.gov/cholera/treatment/index.html. Accessed 23 October 2018.
Dutta D et al. Vibrio cholerae non-O1, non-O139 serogroups and cholera-like diarrhea, Kolkata, India. Emerg Infect Dis 2013; 19: 464-467.
Dick MH et al. Review of two decades of cholera diagnostics - how far have we really come? PLoS Negl Trop Dis 2012; 6: e1845.
Randak CO. An elusive adenylate cyclase complicit in cholera is exposed. J Biol Chem 2018; 293: 12960-12961.
Basu I, Mukhopadhyay C. Insights into binding of cholera toxin to GM1 containing membrane. Langmuir 2014; 30: 15244-15252.
Wand AM et al. Fucosylation and protein glycosylation create functional receptors for cholera toxin. Elife 2015; 29: e09545.
Muanprasat C, Chatsudthipong V. Cholera: pathophysiology and emerging therapeutic targets. Future Med Chem 2013; 5: 781-798.
Moon C et al. Drug-induced secretory diarrhea: a role for CFTR. Pharmacol Res 2015; 102: 107-112.
Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 2003; 111: 931-943.
Clemens JD et al. Cholera. Lancet 2017; 390: 1539-1549.
Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev 1996; 60: 167-215.
Saha DR et al. Detection of faecal leucocytes and erythrocytes from stools of cholera patients suggesting an evidence of an inflammatory response in cholera. Indian J Med Res 2000; 112: 5-8.
Qadri F et al. Increased levels of inflammatory mediators in children and adults infected with Vibrio cholerae O1 and O139. Clin Diagn Lab Immunol 2002; 9: 221-229.
Soriani M et al. Contribution of the ADP-ribosylating and receptor-binding properties of cholera-like enterotoxins in modulating cytokine secretion by human intestinal epithelial cells. Microbiology 2002; 148: 667-676.
Rocha MF et al. Role of mast cells and pro-inflammatory mediators on the intestinal secretion induced by cholera toxin. Toxicon 2003; 42: 183-189.
Kim KJ et al. Cholera toxin breakdowns oral tolerance via activation of canonical NF-kappaB. Cell Immunol 2013; 285: 92-99.
Harrison LM et al. Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activation. Infect Immun 2008; 76: 5524-5534.
Satitsri S et al. Pathophysiological mechanisms of diarrhea caused by the Vibrio cholerae O1 El Tor variant: an in vivo study in mice. Virulence 2016; 7: 789-805.
Kelly MR Jr et al. The impact of spatial arrangements on epidemic disease dynamics and intervention strategies. J Biol Dyn 2016; 10: 222-249.
Thiagarajah JR et al. Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol 2015; 12: 446-457.
Cheng SX. Calcium-sensing receptor: a new target for therapy of diarrhea. World J Gastroenterol 2016; 22: 2711-2724.
Tradtrantip L et al. Antidiarrheal efficacy and cellular mechanisms of a Thai herbal remedy. PLoS Negl Trop Dis 2014; 8: e2674.
Griggs DW et al. Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea. J Pharmacol Exp Ther 2016; 357: 423-431.
Thompson KE et al. Prevention and treatment of secretory diarrhea by the lysophosphatidic acid analog Rx100. Exp Biol Med 2018; 243: 1056-1065.
World Health Organization. Editorial note: Cholera, a public health priority. Wkly Epidemiol Rec 2015; 40: 517-44.
Teoh SL et al. Global economic evaluation of oral cholera vaccine: a systematic review. Hum Vaccin Immunother 2018; 14: 420-429.
Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000; 62: 535-572.
Kunzelmann K. The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 1999; 137: 1-70.
Cil O et al. CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation. Cell Mol Gastroenterol Hepatol 2016; 2: 317-327.
Thiagarajah JR, Verkman AS. CFTR inhibitors for treating diarrheal disease. Clin Pharmacol Ther 2012; 92: 287-290.
Muangnil P et al. Fungal metabolite zearalenone as a CFTR inhibitor and potential therapy of secretory diarrheas. Biochem Pharmacol 2018; 150: 293-304.
Pongkorpsakol P et al. Inhibition of intestinal chloride secretion by piperine as a cellular basis for the anti-secretory effect of black peppers. Pharmacol Res 2015; 100: 271-280.
Thiagarajah JR et al. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 2004; 126: 511-519.
Verkman AS et al. CFTR chloride channel drug discovery-inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des 2006; 12: 2235-2247.
Tradtrantip L et al. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol 2010; 77: 69-78.
Muanprasat C et al. Novel action of the chalcone isoliquiritigenin as a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor: potential therapy for cholera and polycystic kidney disease. J Pharmacol Sci 2012; 118: 82-91.
Cil O et al. Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins. FASEB J 2017; 31: 751-760.
Yu B et al. Plumbagin prevents secretory diarrhea by inhibiting CaCC and CFTR channel activities. Front Pharmacol 2019; 10: 1181.
Pongkorpsakol P et al. Inhibition of cAMP-activated intestinal chloride secretion by diclofenac: cellular mechanism and potential application in cholera. PLoS Negl Trop Dis 2014; 8: e3119.
Hardie DG, Ashford ML. AMPK: regulating energy balance at the cellular and whole body levels. Physiology (Bethesda) 2014; 29: 99-107.
Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol 2017; 45: 31-37.
Fu X et al. AMP-activated protein kinase mediates myogenin expression and myogenesis via histone deacetylase 5. Am J Physiol Cell Physiol 2013; 305: C887-C895.
Wang S et al. Resveratrol enhances brown adipocyte formation and function by activating AMP-activated protein kinase (AMPK) alpha1 in mice fed high-fat diet. Mol Nutr Food Res 2017; 61: 1600746.
Dzeja PP et al. Developmental enhancement of adenylate kinase AMPK metabolic signaling axis supports stem cell cardiac differentiation. PLoS One 2011; 6: e19300.
Walker J et al. Activation of AMP-activated protein kinase reduces cAMP-mediated epithelial chloride secretion. Am J Physiol Gastrointest Liver Physiol 2003; 285: G850-G860.
Sun X et al. AMPK improves gut epithelial differentiation and barrier function via regulating Cdx2 expression. Cell Death Differ 2017; 24: 819-831.
Kongsuphol P et al. Regulation of Cl− secretion by AMPK in vivo. Pflugers Arch 2009; 45: 1071-1078.
Rogers AC et al. Activation of AMPK inhibits cholera toxin stimulated chloride secretion in human and murine intestine. PLoS One 2013; 8: e69050.
Hallows KR et al. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. J Biol Chem 2003; 278: 998-1004.
Pongkorpsakol P et al. Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. Eur J Pharmacol 2017; 5: 94-104.
Pariwat P et al. A natural plant-derived dihydroisosteviol prevents cholera toxin-induced intestinal fluid secretion. J Pharmacol Exp Ther 2008; 324: 798-805.
Yibcharoenporn C et al. Discovery of a novel chalcone derivative inhibiting CFTR chloride channel via AMPK activation and its anti-diarrheal application. J Pharmacol Sci 2019; 140: 273-283.
Muanprasat C et al. Activation of AMPK by chitosan oligosaccharide in intestinal epithelial cells: mechanism of action and potential applications in intestinal disorders. Biochem Pharmacol 2015; 96: 225-236.
Chinnapen DJ et al. Rafting with cholera toxin: endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol Lett 2007; 266: 129-137.
Merritt EA et al. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci 1994; 3: 166-175.
Minke WE et al. Structure-based exploration of the ganglioside GM1 binding sites of Escherichia coli heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists. Biochemistry 1999; 38: 5684-5692.
Mitchell DD et al. 3,5-substituted phenyl galactosides as leads in designing effective cholera toxin antagonists; synthesis and crystallographic studies. Bioorg Med Chem 2004; 12: 907-920.
Zhang Z et al. Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor binding of cholera toxin. J Am Chem Soc 2002; 124: 12991-12998.
Polyzos A et al. Biofunctionalized surfactant mesophases as polyvalent inhibitors of cholera toxin. Bioconjug Chem 2007; 18: 1442-1449.
Das S et al. Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera. PLoS Negl Trop Dis 2018; 12: e0006266.
Sarwar S et al. Zinc oxide nanoparticles provide anti-cholera activity by disrupting the interaction of cholera toxin with the human GM1 receptor. J Biol Chem 2017; 292: 18303-18311.
Negi R et al. Oral zinc supplements are ineffective for treating acute dehydrating diarrhoea in 5-12-year-olds. Acta Paediatr 2015; 104: e367-e371.
Araújo TS et al. Antidiarrheal activity of cashew GUM, a complex heteropolysaccharide extracted from exudate of Anacardium occidentale L. in rodents. J Ethnopharmacol 2015; 174: 299-307.
Araújo TSL et al. Biopolymer extracted from Anadenanthera colubrina (red angico gum) exerts therapeutic potential in mice: antidiarrheal activity and safety assessment. Pharmaceuticals (Basel) 2020; 13: 17.
Bezerra FF et al. Antidiarrheal activity of a novel sulfated polysaccharide from the red seaweed Gracilaria cervicornis. J Ethnopharmacol 2018; 224: 27-35.
Leódido AC et al. The efficacy of a sulphated polysaccharide fraction from Hypnea musciformis against diarrhea in rodents. Int J Biol Macromol 2016; 86: 865-875.
Costa DS et al. Sulfated polysaccharide isolated from the seaweed Gracilaria caudata exerts an antidiarrhoeal effect in rodents. Basic Clin Pharmacol Toxicol 2016; 118: 440-448.
Sousa NA et al. The efficacy of a sulphated polysaccharide fraction from Hypnea musciformis against diarrhea in rodents. Int J Biol Macromol 2016; 86: 865-875.
Fan E et al. Exploration of the GM1 receptor-binding site of heat-labile enterotoxin and cholera toxin by phenyl-ring-containing galactose derivatives. Acta Crystallogr Sect D Biol Crystallogr 2001; 57: 201-212.
Sinclair HR et al. Sialyloligosaccharides inhibit cholera toxin binding to the GM1 receptor. Carbohydr Res 2008; 343: 2589-2594.
Negreiros PS et al. Antidiarrheal activity of α-terpineol in mice. Biomed Pharmacother 2019; 110: 631-640.
Costa DS et al. Antidiarrheal activity of farnesol in rodents: pharmacological actions and molecular docking. Eur J Pharmacol 2020; 874: 172986.
Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009; 155: 11-17.
Turvill J, Farthing M. Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport. Eur J Gastroenterol Hepatol 1997; 9: 877-880.
Kang G. Chapter 1.4 - Therapy of viral gastroenteritis. In: Svensson L et al. eds. Viral Gastroenteritis: Molecular Epidemiology and Pathogenesis. Cambridge, UK: Academic Press, 2016: 73-88.
Primi MP et al. Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment Pharmacol Ther 1999; 6: 3-7.
Salazar-Lindo E et al. Racecadotril in the treatment of acute watery diarrhea in children. New Engl J Med 2000; 343: 463-467.
Alam NH et al. Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial. Gut 2003; 52: 1419-1423.
Fazil MH, Singh DV. Vibrio cholerae infection, novel drug targets and phage therapy. Future Microbiol 2011; 6: 1199-1208.
Hung DT et al. Small-molecule inhibitor of Vibrio Cholerae virulence and intestinal colonization. Science 2005; 310: 670-674.
Conner JG et al. Staying alive: Vibrio cholerae's cycle of environmental survival, transmission, and dissemination. Microbiol Spectr 2016; 4: 1-48.
Stonehouse EA et al. H-NS binding and repression of the ctx promoter in Vibrio cholerae. J Bacteriol 2011; 193: 979-988.
Shakhnovich EA et al. Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci U S A 2007; 104: 2372-2377.
Krukonis ES, DiRita VJ. From motility to virulence: sensing and responding to environmental signals in Vibrio cholerae. Curr Opin Microbiol 2003; 6: 186-190.
Skorupski K, Taylor RK. Control of ToxR virulence regulon in Vibrio cholerae by environmental stimuli. Mol Microbiol 1997; 25: 1003-1009.
Thomson JJ et al. A small unstructured region in Vibrio cholerae ToxT mediates the response to positive and negative effectors and ToxT proteolysis. J Bacteriol 2015; 197: 654-668.
Chatterjee A et al. Effect of fatty acids and cholesterol present in bile on expression of virulence factors and motility of Vibrio cholerae. Infect Immun 2007; 75: 1946-1953.
Guentzel MN et al. Use of fluorescent antibody in studies of immunity to cholera in infant mice. Infect Immun 1977; 15: 539-548.
Gunn JS. Mechanisms of bacterial resistance and response to bile. Microbes Infect 2000; 2: 907-913.
Butler SM, Camilli A. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat Rev Microbiol 2005; 3: 611-620.
Plecha SC, Withey J. Mechanism for inhibition of Vibrio cholerae ToxT activity by the unsaturated fatty acid components of bile. J Bacteriol 2015; 197: 1716-1725.
Withey JH et al. Conjugated linoleic acid reduces cholera toxin production in vitro and in vivo by inhibiting Vibrio Cholerae ToxT activity. Antimicrob Agents Chemother 2015; 59: 7471-7476.
Woodbrey AK et al. A modified ToxT inhibitor reduces Vibrio cholerae virulence in vivo. Biochemistry 2018; 57: 5609-5615.
Chatterjee S et al. Capsaicin, a potential inhibitor of cholera toxin production in Vibrio cholerae. FEMS Microbiol Lett 2010; 306: 54-60.
Erfanimanesh S et al. Capsaicin inhibitory effects on Vibrio cholerae toxin genes expression. Avicenna J Phytomed 2019; 9: 187-194.
Luscher B et al. ADP-ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease. Chem Rev 2018; 118: 1092-1136.
Deng Q, Barbieri JT. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol 2008; 62: 271-288.
Freissmuth M, Gilman G. Mutations of Gs alpha designed to alter the reactivity of the protein with bacterial toxins. Substitutions at ARG187 result in loss of GTPase activity. J Biol Chem 1989; 264: 21907-21914.
Corda D, Di Girolamo M. Mono-ADP-ribosylation: a tool for modulating immune response and cell signaling. Sci STKE 2002; 2002: pe53.
Mashimo M et al. Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases. DNA Repair (Amst) 2014; 23: 88-94.
Moss J et al. ADP-ribosylarginine hydrolases and ADP-ribosyltransferases. Partners in ADP-ribosylation cycles. Adv Exp Med Biol 1997; 419: 25-33.
Watanabe K et al. Enhanced sensitivity to cholera toxin in female ADP-ribosylarginine hydrolase (ARH1)-deficient mice. PLoS One 2018; 13: e0207693.
Kato J et al. Enhanced sensitivity to cholera toxin in ADP-ribosylarginine hydrolase-deficient mice. Mol Cell Biol 2007; 27: 5534-5543.
Morinaga N et al. Resveratrol, a natural polyphenolic compound, inhibits cholera toxin-induced cyclic AMP accumulation in Vero cells. Toxicon 2010; 56: 29-35.
Saito T et al. Inhibition by apple polyphenols of ADP-ribosyltransferase activity of cholera toxin and toxin-induced fluid accumulation in mice. Microbiol Immunol 2002; 46: 249-255.
Oi H et al. Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc Natl Acad Sci U S A 2002; 99: 3042-3046.
Laloo D, Hemalatha S. Ethnomedicinal plants used for diarrhea by tribals of Meghalaya, Northeast India. Pharmacogn 2011; 5: 147-154.
Komiazyk M et al. Use of plant extracts to control and treat AB 5 enterotoxin-related diarrhea. Pol J Microbiol 2014; 63: 3-14.
Komiazyk M et al. Neutralization of cholera toxin by Rosaceae family plant extracts. BMC Complement Altern Med 2019; 19: 140.
Rehman N et al. Mechanisms underlying the antidiarrheal, antispasmodic and bronchodilator activities of Fumaria parviflora and involvement of tissue and species specificity. J Ethnopharmacol 2012; 144: 128-137.
Khatun H et al. Antidiabetic and antidiarrheal effects of the methanolic extract of Phyllanthus reticulatus leaves in mice. Asian Pac J Reprod 2014; 3: 121-127.
Jose D et al. Development of a novel herbal formulation to inhibit biofilm formation in toxigenic Vibrio cholerae. J Food Prot 2017; 80: 1933-1940.
Velázquez C et al. Management of secretory diarrhea. Curr Concepts Colon Disord 2012; 20: 67-84.
Velázquez C et al. Antisecretory activity of plants used to treat gastrointestinal disorders in Mexico. J Ethnopharmacol 2006; 103: 66-70.
Bhattacharya D et al. Anti-virulence activity of polyphenolic fraction isolated from Kombucha against Vibrio cholerae. Microb Pathog 2020; 140: 103927.
Noumi E et al. Phytochemical composition, anti-biofilm and anti-quorum sensing potential of fruit, stem and leaves of Salvadora persica L. methanolic extracts. Microb Pathog 2017; 109: 169-176.
Thakur P et al. Attenuation of adhesion, quorum sensing and biofilm mediated virulence of carbapenem resistant Escherichia coli by selected natural plant products. Microb Pathog 2016; 92: 76-85.
Lahiri SC, Dutta NK. Berberine and chloramphenicol in the treatment of cholera and severe diarrhoea. J Indian Med 1967; 48: 1-11.
Akhter MH et al. Anti-inflammatory effect of berberine in rats injected locally with cholera toxin. Indian J Med Res 1977; 65: 133-141.
Sabir M et al. Antagonism of cholera toxin by berberine in the gastrointestinal tract of adult rats. Indian J Med Res 1977; 65: 305-313.
Sack RB, Froehlich JL. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect Immun 1982; 35: 471-475.
Khin-Maung Uet al. Clinical trial of berberine in acute watery diarrhoea. Br Med J Clin Res Ed 1985; 291: 1601-1605.
Narendrakumar L et al. Tryptanthrin, a potential biofilm inhibitor against toxigenic Vibrio cholerae, modulating the global quorum sensing regulator, LuxO. Biofouling 2019; 35: 1093-1103.
Paredes A et al. A plant from the altiplano of Northern Chile Senecio nutans, inhibits the Vibrio cholerae pathogen. Springerplus 2016; 5: 1788.
Santana LAB et al. Antidiarrheal effects of water-soluble proteins from Plumeria pudica latex in mice. Biomed Pharmacother 2018; 97: 1147-1154.
Bag PK et al. In vivo fluid accumulation-inhibitory, anticolonization and anti-inflammatory and in vitro biofilm-inhibitory activities of methyl gallate isolated from Terminalia chebula against fluoroquinolones resistant Vibrio cholerae. Microb Pathog 2019; 128: 41-46.
Velázquez C et al. Antisecretory activity from the flowers of Chiranthodendron pentadactylon and its flavonoids on intestinal fluid accumulation induced by Vibrio cholerae toxin in rats. J Ethnopharmacol 2009; 126: 455-458.
Sarker P et al. Treatment with Entinostat heals experimental cholera by affecting physical and chemical barrier functions of intestinal epithelia. Antimicrob Agents Chemother 2017; 61: e02570-16.
Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
Chakraborty K et al. Bacterial exotoxins downregulate cathelicidin (hCAP-18/LL- 37) and human beta-defensin 1 (HBD-1) expression in the intestinal epithelial cells. Cell Microbiol 2008; 10: 2520-2537.
Sousa FBM et al. H2S is a key antisecretory molecule against cholera toxin-induced diarrhoea in mice: evidence for non-involvement of the AC/cAMP/PKA pathway and AMPK. Nitric Oxide 2018; 76: 152-163.
Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov 2015; 14: 329-345.
Zaorska E et al. Hydrogen sulfide in pharmacotherapy, beyond the hydrogen sulfide-donors. Biomolecules 2020; 10: 323.
Szabo C, Papapetropoulos A. International union of basic and clinical pharmacology. CII: pharmacological modulation of H2S levels: H2S donors and H2S biosynthesis inhibitors. Pharmacol Ver 2017; 69: 497-564.
Sawasvirojwong S et al. An adult mouse model of Vibrio cholerae-induced diarrhea for studying pathogenesis and potential therapy of cholera. PLoS Negl Trop Dis 2013; 7: e2293.
Thiagarajah JR, Verkman AS. New drug targets for cholera therapy. Trends Pharmacol Sci 2005; 265: 172-175.
فهرسة مساهمة: Keywords: cholera; cholera toxin; molecular mechanism
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Rehydration Solutions)
0 (Virulence Factors)
9012-63-9 (Cholera Toxin)
تواريخ الأحداث: Date Created: 20200802 Date Completed: 20210728 Latest Revision: 20210728
رمز التحديث: 20221213
DOI: 10.1111/jphp.13344
PMID: 32737883
قاعدة البيانات: MEDLINE
الوصف
تدمد:2042-7158
DOI:10.1111/jphp.13344